Sotera Health (NASDAQ:SHC) Given “Overweight” Rating at Piper Sandler

Sotera Health (NASDAQ:SHC)‘s stock had its “overweight” rating restated by stock analysts at Piper Sandler in a research report issued on Friday,Benzinga reports. They presently have a $25.00 target price on the stock, up from their previous target price of $22.00. Piper Sandler’s target price suggests a potential upside of 32.73% from the stock’s current price.

Several other research analysts also recently weighed in on SHC. UBS Group set a $19.00 target price on shares of Sotera Health in a research note on Wednesday, June 24th. The Goldman Sachs Group assumed coverage on shares of Sotera Health in a research report on Friday, June 5th. They issued a “buy” rating and a $20.00 price objective for the company. Barclays reissued an “overweight” rating on shares of Sotera Health in a research note on Friday. JPMorgan Chase & Co. raised their target price on shares of Sotera Health from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Friday. Finally, Weiss Ratings upgraded Sotera Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, July 9th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $20.88.

Sotera Health Price Performance

NASDAQ:SHC traded down $0.07 during trading hours on Friday, reaching $18.84. 1,102,288 shares of the company traded hands, compared to its average volume of 2,867,544. The company has a debt-to-equity ratio of 3.56, a current ratio of 2.82 and a quick ratio of 2.54. The firm’s 50-day moving average is $17.07 and its 200-day moving average is $16.31. The stock has a market cap of $5.37 billion, a P/E ratio of 45.94 and a beta of 1.77. Sotera Health has a 1-year low of $12.94 and a 1-year high of $19.85.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.02. Sotera Health had a return on equity of 39.73% and a net margin of 9.91%.The company had revenue of $321.38 million during the quarter, compared to analysts’ expectations of $309.70 million. During the same period in the previous year, the firm posted $0.20 earnings per share. The business’s revenue for the quarter was up 9.2% compared to the same quarter last year. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. Equities research analysts expect that Sotera Health will post 0.87 earnings per share for the current fiscal year.

Insider Activity at Sotera Health

In other news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of the stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $15.17, for a total transaction of $193,194,516.17. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 15.36% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Sotera Health

A number of large investors have recently bought and sold shares of SHC. IFP Advisors Inc raised its stake in Sotera Health by 1,105.6% during the fourth quarter. IFP Advisors Inc now owns 1,495 shares of the company’s stock worth $26,000 after purchasing an additional 1,371 shares during the period. Rothschild Investment LLC purchased a new position in shares of Sotera Health in the 4th quarter worth $27,000. Root Financial Partners LLC boosted its holdings in Sotera Health by 217.5% in the first quarter. Root Financial Partners LLC now owns 2,124 shares of the company’s stock valued at $30,000 after acquiring an additional 1,455 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Sotera Health by 831.4% during the second quarter. EverSource Wealth Advisors LLC now owns 3,288 shares of the company’s stock valued at $37,000 after acquiring an additional 2,935 shares during the period. Finally, Eurizon Capital SGR S.p.A. acquired a new stake in Sotera Health during the fourth quarter worth about $40,000. Hedge funds and other institutional investors own 91.03% of the company’s stock.

More Sotera Health News

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Second-quarter revenue rose 9.2% year over year to $321.4 million, ahead of the $309.7 million consensus estimate. Adjusted EPS was $0.26, topping expectations of $0.24 and increasing from $0.20 a year earlier. Sotera Health Company Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Profitability improved significantly: GAAP net income increased to $53.6 million from $8.0 million, while adjusted EBITDA grew 10% and the adjusted EBITDA margin expanded to 51.6%.
• Positive Sentiment: Growth was broad-based. Sterigenics revenue increased 7.0% on a constant-currency basis, Nordion grew 16.7%, and Nelson Labs rose 5.4%. Nordion also delivered a 160-basis-point improvement in segment margin.
• Positive Sentiment: Sotera Health raised its 2026 outlook, now expecting constant-currency revenue growth of 5.25% to 6.75%, adjusted EBITDA growth of 5.75% to 7.25%, and adjusted EPS of $0.95 to $1.01 versus the prior midpoint of expectations. Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
• Positive Sentiment: Balance-sheet trends improved modestly. Net leverage declined to 3.0x, within the company’s long-term target range, liquidity reached approximately $950 million, and a term-loan repricing is expected to reduce annual interest expense by about $3.5 million.
• Neutral Sentiment: The earnings call highlighted confidence in demand for Sotera Health’s mission-critical sterilization, isotope and laboratory-testing services, but future results remain dependent on supply availability, inflation, foreign exchange and execution across its business units. Sotera Health Q2 2026 Earnings Call Transcript
• Negative Sentiment: Total debt remained high at approximately $2.2 billion. Investors also continue to face litigation, regulatory and reputational risks tied to ethylene oxide emissions, while higher costs pressured Nelson Labs’ first-half segment income.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.